Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Size: px
Start display at page:

Download "Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH"

Transcription

1 Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH

2 MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Board, which is composed of the six ICH parties (EU, EFPIA, MHLW, JPMA, FDA, PhRMA), the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer). MSSO-DI

3 Disclaimer and Copyright Notice This presentation is protected by copyright and may be used, reproduced, incorporated into other works, adapted, d modified, d translated t or distributed ib t d under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided. The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation. The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder. MSSO-DI

4 Course Overview MedDRA background MedDRA s structure, scope, and characteristics MedDRA maintenance Coding conventions Synonym lists QA of coding MedDRA Term Selection: Points to Consider document Hands-on coding exercises MSSO-DI

5 MedDRA Background

6 What is MedDRA? Med = Medical D = Dictionary for R = Regulatory A = Activities MSSO-DI

7 Objectives for MedDRA Development Result of an ICH initiative (M1) To provide: An international multi-lingual terminology Standardized di d communication between industry and regulators Support of electronic submissions Application through all phases of the development cycle MSSO-DI

8 Objectives for MedDRA Development (cont) To provide (cont): Classification for a wide range of clinical i l information Support for multiple medical product areas A terminology that saves time, resources, and money MSSO-DI

9 MedDRA and the MSSO International support and development of terminology Foster use of MedDRA through communications and educational offerings Custodians, not owners, of the terminology JMO (partner organization for Japanese- language MedDRA) Governed by a Management Board (industry, regulators, multi-national, other interested parties) MSSO-DI

10 MedDRA Definition MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation. MSSO-DI

11 US FDA Regulatory Statust Used in several databases including FAERS (drugs and biologics), VAERS (vaccines), and CAERS (foods, dietary supplements, cosmetics) FAERS and VAERS accept LLTs and PTs CAERS accepts PTs Recommended terminology for adverse event reporting in several Proposed Rules Japanese Ministry of Health, Labour and Welfare Mandatory use in electronic reporting LLTs and PTs accepted MSSO-DI

12 Regulatory Status (cont) European Union EudraVigilance database Clinical trial SUSARs (Suspected Unexpected Serious Adverse Reactions) Post-authorization Individual Case Safety Reports (ICSRs) Use MedDRA LLTs (current version or the one previous to it) New PV legislation l i covers suspected adverse reactions from: Use inside and outside terms of marketing authorization Overdose, misuse, abuse, and medication errors Occupational exposures Good pharmacovigilance practices (GVP) specifically mention MedDRA MSSO-DI

13 Regulatory Status t (cont) European Union (cont) Used in interface between EudraVigilance and EU Risk Management Plan Used throughout Summary of Product Characteristics (labeling) ICH M4E Guideline on Common Technical Document Recommended in adverse event summary tables Canada Recommended/preferred terminology for adverse reaction reporting and Product Monograph (labeling) MSSO-DI

14 MedDRA Overview

15 Scope of MedDRA Not a drug dictionary Patient demographic terms Clinical trial study design terms OUT IN Medical conditions Indications Investigations (tests, results) Medical and surgical procedures Medical, social, family history Medication errors Product quality issues Device-related issues Pharmacogenetic terms Toxicologic issues Standardized queries Frequency qualifiers Numerical values for results Severity descriptors Not an equipment, device, diagnostic product dictionary MSSO-DI

16 MedDRA Structure System Organ Class (SOC) (26) High Level Group Term (HLGT) (334) High Level Term (HLT) (1,717) Preferred Term (PT) (20,057) 057) Lowest Level Term (LLT) (71,326) MedDRA Version 16.0 MSSO-DI

17 MedDRA Term Level Definitions SOC - Highest level of the terminology, and representing an anatomical or physiological system, etiology, or purpose HLGT - Subordinate to SOC, superordinate grouping for one or more HLTs HLT - Subordinate to HLGT, superordinate grouping for one or more PTs PT - Represents a single medical concept LLT - Lowest level of the terminology, related to a single PT as a synonym, lexical variant, or quasi- synonym (Note: All PTs have an identical LLT) MSSO-DI

18 System Organ Classes Blood and lymphatic system disorders Cardiac disorders Congenital, familial and genetic disorders Ear and labyrinth disorders Endocrine disorders Eye disorders Gastrointestinal disorders General disorders and administration site conditions Hepatobiliary disorders Immune system disordersd Infections and infestations Injury, poisoning and procedural complications Investigations Metabolism and nutrition disorders Musculoskeletal and connective tissue disorders Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nervous system disorders Pregnancy, puerperium and perinatal conditions Psychiatric i disorders d Renal and urinary disorders Reproductive system and breast disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Social circumstances Surgical and medical procedures Vascular disorders MSSO-DI

19 High Level Group Term Subordinate only to SOCs and superordinate grouping for one or more HLTs SOC Cardiac disorders HLGT HLGT HLGT Coronary artery Cardiac Cardiac valve disorders arrhythmias disorders MSSO-DI

20 High Level Term Subordinate to HLGTs and superordinate grouping for the PTs linked to it SOC Cardiac disorders HLGT Cardiac arrhythmias HLT HLT HLT Rate and rhythm disorders NEC Cardiac conduction disorders Supraventricular arrhythmias MSSO-DI

21 Examples of PTs SOC = Cardiac disorders HLGT = Cardiac arrhythmias HLT = Rate and rhythm disorders NEC PT PT PT Arrhythmia Bradycardia Tachyarrhythmia MSSO-DI

22 Examples of LLTs SOC = Cardiac disorders d HLGT = Cardiac arrhythmias HLT = Rate and rhythm disorders NEC PT = Arrhythmia LLT LLT Arrhythmia LLT Dysrhythmias NOS Arrhythmia LLT (Non-current) Other specified cardiac dysrhythmias MSSO-DI

23 Non-Current Terms Non-current tterms are flagged at tthe LLT level within MedDRA Not recommended for continued use Retained within the terminology to preserve e historical data for retrieval e and analysis Terms that are vague, ambiguous, out- dated, d truncated, t or misspelled Terms derived from other terminologies that do not fit MedDRA rules MSSO-DI

24 MedDRA Codes Each MedDRA term assigned an 8-digit numeric code The code is non-expressive Codes can fulfill a data field in various electronic submission types (e.g., E2B) Initially assigned alphabetically by term starting with New terms are assigned sequentially Supplemental terms are assigned codes MSSO-DI

25 A Multi-Axial Terminology Multi-axial i l = the representation ti of a medical concept in multiple SOCs Allows grouping by different classifications Allows retrieval and presentation via different data sets Purpose of Primary SOC Determines which SOC will represent a PT during cumulative data outputs Is used to support consistent data presentation for reporting to regulators MSSO-DI

26 A Multi-Axial Terminology (cont) SOC = Respiratory, thoracic and mediastinal disorders SOC = Infections and infestations HLGT = Respiratory tract infections HLGT = Viral infectious disorders HLT = Viral upper respiratory tract infections HLT = Influenza viral infections PT = Influenza MSSO-DI

27 A Multi-Axial Terminology (cont) PTs in the following SOCs only appear in that particular SOC and not in others, i.e., they are not multi-axial Investigations Surgical and medical procedures Social circumstances MSSO-DI

28 Rules for Primary SOC Allocation PTs for diseases, signs and symptoms are assigned to prime manifestation site SOC Congenital and hereditary anomalies terms have SOC Congenital, familial l and genetic disorders d as Primary SOC Neoplasms terms have SOC Neoplasms benign, malignant and unspecified (incl cysts and polyps) as Primary SOC Exception: Cysts and polyps have prime manifestation site SOC as Primary SOC Infections and infestations terms have SOC Infections and infestations as Primary SOC MSSO-DI

29 Primary SOC Priority If a PT links to more than one of the exceptions, the following priority will be used dto determine primary SOC: 1 st : Congenital, familial and genetic disorders 2 nd : Neoplasms benign, malignant and unspecified (incl cysts and polyps) 3 rd : Infections and infestations MSSO-DI

30 SOC Congenital, familial l and genetic disorders - Example PT HLT HLGT SOC Congenital Viral infections Infections and Congenital, HIV congenital infestations familial and infection congenital genetic disorders (P) Congenital Neonatal and Pregnancy, neonatal infections perinatal conditions puerperium and perinatal conditions Retroviral infections Viral infectious disorders Infections and infestations Acquired immunodeficiency syndromes Immunodeficiency Immune syndromes system disorders MSSO-DI

31 Conditions vs. Investigations PT HLT HLGT SOC Pregnancy test positive Reproductive hormone analyses Endocrine investigations (incl sex hormones) Investigations Pregnancy Normal pregnancy, labour and delivery Pregnancy, labour, delivery and postpartum t conditions Pregnancy, puerperium and perinatal conditions Be careful to distinguish between a condition and an investigation or a result of an investigation MSSO-DI

32 Standardised MedDRA Queries (SMQs) Groupings of terms from more than one SOC related to defined medical condition or area of interest Examples: Lack of efficacy/effect; Rhabdomyolysis/myopathy; Osteonecrosis 90 SMQ topics available in MedDRA v16.0 More information on MSSO Web site MSSO-DI

33 MedDRA Maintenance

34 MedDRA Maintenance MedDRA is a user responsive terminology Subscribers may submit change requests to the MSSO for consideration Core and basic subscribers: 100 change requests (CRs) per month For simple changes (PT and LLT levels), notification of supplemental change within 7-10 working days Weekly supplemental l changes posted on MSSO Web site Complex changes above PT level received all year round. Posted for subscribers comments mid-year. MSSO-DI

35 MedDRA Maintenance (cont) Twice yearly official updates 1S September X1 X.1 release (Simple changes only) 1 March X.0 release (Complex and simple changes) MSSO-DI

36 WebCR Web-based based tool for Change Requests (CR) URL: Via the Change Request Information page Ability to submit CRs online Immediate confirmation Review unsubmitted CRs online Ability to query CR history back to v5.1 MSSO-DI

37 Change Request Justification Statements Justification statement always required Inadequate justification Term does not exist in MedDRA Adequate justification statement of need Support with definitions and references (PDFs preferred) Examples of need: Term needed to code an indication Concept is being reported in a clinical trial MSSO-DI

38 Proactive MedDRA Maintenance What is the proactive approach? Corrections/improvements made internally by the MSSO General changes suggested by users Submitting ideas Send to MSSO Help Desk. Justification is helpful. Example: Consider consolidation of HLTs with only one PT Evaluation of proposals MSSO is not obligated to respond Proactive approach does not replace usual CR process MSSO-DI

39 MedDRA Version Analysis Tool (MVAT) Web-based ( Free to all subscribers Allows for comparison of any two versions Features Version Report Generator (produces exportable report comparing any two versions) Data Impact Report (identifies changes to a specific set of MedDRA terms or codes uploaded to MVAT) Search Term Change (identifies changes to a single MedDRA term or code) MSSO-DI

40 MSSO s MedDRA Browsers MedDRA Desktop Browser Download from MSSO Web site View/search MedDRA and SMQs Export functionality MedDRA Web-Based Browser Requires specific user ID and password Access to all MedDRA versions in English and available EU languages (and Chinese, if subscribed) View/search MedDRA and SMQs Export functionality MSSO-DI

41 MedDRA Browser Demonstration and Instruction

42 Coding Exercises

43 Assessing the Reported Information Consider what is being reported. Is it a: Clinical condition - Diagnosis, sign or symptom? Indication? Test result? Injury? Procedure? The type of report will Medication error? influence the way you Product quality issue? search for a suitable LLT. It may indicate in which Social circumstance? SOC you expect to find Device issue? the closest match. Procedural complication? Is it a combination of these? MSSO-DI

44 MedDRA Browsing Tips First, try using actual words from reporter Use top-down and bottom-up approaches Look at the neighbors Check the hierarchy Consider synonyms, e.g., Liver and Hepatic Use word stems, e.g., Pancrea Search different word orders, and, or, etc. Use available resources for difficult verbatim terms (web search, medical dictionaries, colleagues) MSSO-DI

45 Exercise 1 The patient states she has been experiencing headaches, dizziness and vertigo. LLT PT LLT PT LLT PT MSSO-DI

46 Exercise 2 Lab results indicate an increase in erythrocytes. LLT PT MSSO-DI

47 Exercise 3 Drug was contaminated ated with Staphylococcus. LLT PT MSSO-DI

48 Exercise 4 A three year old boy was admitted for loratadine toxicity ty after accidentally ingesting the remaining tablets in the bottle. LLT PT LLT PT MSSO-DI

49 Exercise 5 The epate patient s tsinsulin pump p was noted to be broken. LLT PT MSSO-DI

50 Coding with MedDRA

51 What Does MedDRA Offer? Size and specificity ( granularity ) Hierarchy/grouping terms Support SOCs widen data collection/analysis options Up-to-date and medically rigorous User-responsive STANDARDIZATION MSSO-DI

52 Why Do We Need Coding Conventions? Differences in medical aptitude of coders Consistency concerns (many more choices to manually code terms in MedDRA compared to older terminologies) Even with an autoencoder, may still need manual coding MSSO-DI

53 Can I Make Coding Conventions Specific to My Company/Product? MedDRA may reduce the need to do this because: Increased size/granularity results in more accurate representation of data Secondary SOC allocations allow for different i views of fthe dt data This type of approach should be done cautiously MSSO-DI

54 Synonym Lists Can be derived d from existing term lists or directly from verbatims For recurring, but unusual, verbatims onetime assignment to a MedDRA term Enforces consistency by limiting choices once MedDRA term is assigned Increases likelihood of autoencoding hit Natural outgrowth of a legacy data conversion Maintenance required MSSO-DI

55 Synonym List Examples Verbatim LLT Comment Throbbing above temple Aching all over head Pulsing pain in head Muscular pain in legs Headache Myalgia of lower extremities LLT Myalgia of lower extremities is a better choice than LLT Muscular pain since it captures both the event and body site MSSO-DI

56 Synonym List Maintenance For new MedDRA versions, run synonyms against new MedDRA LLTs Identify new non-current LLTs that are on synonym list; flag for recoding Identify possible new current direct matches Remaining challenge is to determine if better medical matches have been added (essentially, a manual process) Communicate results to users of synonym y list MSSO-DI

57 QA Reports Allows reviewers to check for consistency y( (both auto-encoded and human-coded terms) Check for adherence to/deviation from coding conventions Check for emerging g drifts/biases Multiple data views (verbatims to coded terms; coded term to verbatims; by SOC, etc.) MSSO-DI

58 MSSO-DI

59 MSSO-DI

60 MedDRA Term Selection: Points to Consider (MTS:PTC) An ICH-endorsed guide for MedDRA users Provides term selection advice for industry and regulatory purposes Objective is to promote accurate and consistent term selection to facilitate a common understanding di of shared data Recommended to be used as the basis for individual id organizations coding conventions MSSO-DI

61 MedDRA Term Selection: PTC (cont) Developed by a working group of the ICH Steering Committee Regulators and industry representatives EU, Japan, USA Canadian observer, MSSO, JMO Updated d twice yearly with each MedDRA release Available on MSSO, JMO, and ICH Web sites English and Japanese Variety of file formats for ease of viewing and editing Summary of Changes document MSSO-DI

62 MTS:PTC Points of Note In some cases with more than one option for selecting terms, a preferred option is identified but this does not limit MedDRA users to applying that option. Organizations ations should be consistent in their choice of option. Section 4.1 Versioning (Appendix) Versioning methodologies Timing of version implementation MSSO-DI

63 General Term Selection Principles Quality of Source Data Quality Assurance Do Not Alter MedDRA Always Select a Lowest Level Term Select Only Current Lowest Level Terms When to Request a Term Use of Medical Judgment in Term Selection Selecting More than One Term Check the Hierarchy Select Terms for All Reported Information, Do Not Add Information MSSO-DI

64 Quality of Source Data Quality Assurance Quality of original information impacts quality of output Obtain clarification of data Can be optimized by careful design of data collection forms and proper training i of staff Organizations coding guidelines should be consistent with MTS:PTC Review of term selection by qualified individuals Human oversight of automated coding results MSSO-DI

65 Do Not Alter MedDRA MedDRA is a standardized terminology with a pre-defined term hierarchy Users must not make ad hoc structural alterations, including changing the primary SOC allocation If terms are incorrectly placed, submit a change request to the MSSO MSSO-DI

66 Always Select a Lowest Level Term Select Only Current LLTs Lowest Level Term that most accurately reflects the reported verbatim information should be selected Degree of specificity may be challenging Example: Abscess on face select Facial abscess, not simply Abscess Select current LLTs only Non-current terms for legacy conversion/historical purposes MSSO-DI

67 When to Request a Term Use of Medical Judgment Avoid company-specific work-arounds for MedDRA deficiencies. If concept not adequately represented in MedDRA, submit Change Request to MSSO. If no exact match in MedDRA, use medical judgment to match to an existing term that adequately represents the concept MSSO-DI

68 Selecting More than One Term Check the Hierarchy Can select more than one LLT to represent reported information. Document procedures. Selecting one term may lead to loss of specificity Selecting more than one term may lead to redundant counts Check the hierarchy above a selected LLT (PT, HLT, HLGT, SOC) to ensure e placement accurately reflects meaning of reported term MSSO-DI

69 Select Terms for All Reported Information Select terms for every AR/AE reported, regardless of causal association Select terms for device-related events, product quality issues, medication errors, medical and social history, investigations and indications as appropriate If diagnosis reported with characteristic signs and symptoms, preferred option is to select term for diagnosis only MSSO-DI

70 Do Not Add Information Do not make diagnosis if only signs/symptoms reported Reported LLT Selected Comment Abdominal pain Abdominal pain, increased serum amylase, and increased serum lipase Serum amylase increased Lipase increased It is inappropriate to assign an LLT for diagnosis of pancreatitis MSSO-DI

71 Pitfalls and Solutions In selecting an LLT for a result of an investigation, parent PT of the selected LLT should contain a qualifier/adjective E.g., present/absent, increased/decreased, etc. If parent PT of selected LLT does not contain a qualifier/adjective, you may have inadvertently tl selected an LLT for the test name, not a result E.g., Blood found in urine, select LLT Blood in urine (PT Blood urine present). Do not select LLT Blood urine (PT Blood urine has no qualifier/ adjective and thus represents the test t name only) l) MSSO-DI

72 Pitfalls and Solutions (cont) Inappropriate terms may be selected by autocoder Review all autocoding carefully Allergic to CAT scan autocoded as LLT Allergic egctocats cats Myocardial infarction in the fall of 2000 autocoded as LLT Myocardial infarction and LLT Fall MSSO-DI

73 FDA-Defined Coding Errors Missed Concepts All medical concepts described after the product is taken should be coded Example: The patient took drug X and developed alopecia, increased LFTs and pancreatitis. Manufacturer only codes alopecia and increased LFTs (missed concept of pancreatitis) Example: The patient took drug X and developed interstitial nephritis which later deteriorated into renal failure. Manufacturer only codes interstitial nephritis (missed renal failure concept) Acknowledgement: Dr. Toni Piazza-Hepp, Office of Surveillance and Epidemiology, CDER MSSO-DI

74 FDA-Defined Coding Errors (cont) Soft Coding Selecting a term which is both less specific and less severe than another MedDRA term is soft coding Example: Liver failure coded as hepatotoxicity or increased LFTs Example: Aplastic anemia coded as unspecified anemia Example: Rash subsequently diagnosed as Stevens Johnson syndrome coded as rash Acknowledgement: Dr. Toni Piazza-Hepp, Office of Surveillance and Epidemiology, CDER MSSO-DI

75 Term Selection Points Diagnoses and Provisional Diagnoses with or without Signs and Symptoms Death and Other Patient Outcomes Suicide and Self-Harm Conflicting/Ambiguous/Vague Information Combination Terms Age vs. Event Specificity Body Site vs. Event Specificity Location Specific vs. Microorganism Specific Information Modification of Pre-existing Conditions Exposures During Pregnancy and Breast Feeding Congenital Terms Neoplasms Medical and Surgical Procedures Investigations MSSO-DI

76 Term Selection Points (cont) Medication/Administration Errors, Accidental Exposures and Occupational Exposures Misuse, Abuse and Addiction Transmission of Infectious Agent via Product Overdose, Toxicity and Poisoning Device-related Terms Drug Interactions No Adverse Effect and Normal Terms Unexpected Therapeutic Effect Modification of Effect Social Circumstances Medical and Social History Indication for Product Use Off Label Use Product Quality Issues MSSO-DI

77 Diagnoses and Provisional Diagnoses SINGLE DIAGNOSIS DEFINITIVE DIAGNOSIS Single diagnosis without signs and symptoms PROVISIONAL DIAGNOSIS Single provisional diagnosis without t signs and symptoms Diagnosis (only possible option) Provisional diagnosis (only possible option) Example: Myocardial infarction select Myocardial infarction Example: Possible myocardial infarction select Myocardial infarction (select term as if definitive diagnosis) Similar principles apply for multiple diagnoses MSSO-DI

78 Diagnoses and Provisional Diagnoses (cont) SINGLE DIAGNOSIS DEFINITIVE DIAGNOSIS Single diagnosis with signs/ symptoms Preferred: Diagnosis only PROVISIONAL DIAGNOSIS Single provisional diagnosis with signs/symptoms Preferred: Provisional diagnosis and signs/symptoms Example: Anaphylactic Example: Possible myocardial reaction with rash, dyspnea, infarction with chest pain, hypotension, and laryngospasm dyspnea, diaphoresis select select Anaphylactic Myocardial infarction Chest reaction pain, Dyspnea, and Diaphoresis Similar principles apply for multiple diagnoses MSSO-DI

79 Diagnoses and Provisional Diagnoses (cont) SINGLE DIAGNOSIS DEFINITIVE DIAGNOSIS Single diagnosis with signs/ symptoms m PROVISIONAL DIAGNOSIS Single provisional diagnosis with signs/symptoms m Alternate: Diagnosis and signs/symptoms Alternate: Signs/symptoms only (as provisional diagnosis may change Example: Anaphylactic reaction Example: Possible myocardial with rash, dyspnea, hypotension, infarction with chest pain, and laryngospasm select dyspnea, diaphoresis select Anaphylactic reaction, Rash, Chest pain, Dyspnea, and Dyspnea, Hypotension, and Diaphoresis Laryngospasm Similar principles apply for multiple diagnoses MSSO-DI

80 What Terms to Select? Sepsis leading to shock from possible spontaneous bacterial peritonitis or bowel perforation Sepsis? Shock? Septic shock? Spontaneous bacterial peritonitis? Bowel perforation? MSSO-DI

81 Diagnoses and Provisional Diagnoses (cont) Always include signs/symptoms not associated with diagnosis Reported LLT Selected Myocardial infarction, chest pain, dyspnea, diaphoresis, ECG changes and jaundice Myocardial infarction Jaundice (note that jaundice is not typically associated with myocardial infarction) MSSO-DI

82 Conflicting/Ambiguous Information First, try to obtain more specific information Reported LLT Selected Comment Hyperkalemia with a serum potassium of 1.6 meq/l GU pain Serum potassium abnormal Pain LLT Serum potassium abnormal covers both of the reported concepts (note: serum potassium of meq/l is a low result, not high) GU could be either genito-urinary or gastric ulcer. If additional information is not available, then select a term to reflect the information that is known, i.e., LLT Pain MSSO-DI

83 Vague Information First, try to obtain more specific information Reported LLT Selected Comment Turned green Unevaluable event Turned green reported alone is vague; this could refer to a patient condition or even to a product (e.g., pills) Patient had a medical problem of unclear type Ill-defined disorder Since it is known that there is some form of a medical disorder, LLT Ill-defined disorder can be selected MSSO-DI

84 What Terms to Select? Clinical l complication of IUD IUD complication (PT Medical device complication)? Intra-uterine death (PT Foetal death)? Unevaluable event? Hypoglycemia (blood glucose = 200 mg/dl) Blood glucose abnormal? Blood glucose increased? Hypoglycemia? MSSO-DI

85 Combination Terms One condition is more specific than the other Reported Arrhythmia due to atrial fibrillation LLT Selected Atrial fibrillation A MedDRA combination term is available Reported Retinopathy due to diabetes LLT Selected Diabetic retinopathy MSSO-DI

86 Combination Terms (cont) If splitting provides more clinical information, select more than one term In all cases of combination terms, apply ppy medical judgment Reported Diarrhea and vomiting Wrist fracture due to fall LLT Selected Diarrhea Vomiting Wrist fracture Fall MSSO-DI

87 What Terms to Select? Retinal ldisease from HIV with near total blindness (R and L) Retinal damage? Retinal disorder? HIV disease? Blindness? HIV retinopathy? Blindness both eyes? MSSO-DI

88 Investigations Medical condition vs. investigation result Reported LLT Selected Comment Hypoglycemia Hypoglycemia LLT Hypoglycemia y links to SOC Metabolism and nutrition disorders Decreased glucose Glucose decreased LLT Glucose decreased links to SOC Investigations MSSO-DI

89 Investigations (cont) Unambiguous investigation result Reported LLT Selected Comment Glucose 40 mg/dl Glucose low Ambiguous investigation result Glucose is clearly below the reference range Reported LLT Selected Comment His glucose was 40 Glucose abnormal No units have been reported. Select LLT Glucose abnormal if clarification cannot be obtained. MSSO-DI

90 Investigations (cont) Investigation results consistent with diagnosis Reported LLT Selected Comment Elevated potassium, K 7.0 mmol/l, and hyperkalemia Hyperkalemia Grouped investigation result terms It is not necessary to select LLT Potassium increased Reported LLT Selected Comment Increased alkaline phosphatase, increased SGPT, increased SGOT and elevated LDH Alkaline phosphatase increased SGPT increased SGOT increased LDH increased Select four individual terms. A single term such as LLT Liver function tests abnormal should not be selected. MSSO-DI

91 What Terms to Select? Testing showed increased serum creatinine and BUN, with increased BUN/creatinine ratio Increased serum creatinine? BUN increased? Blood urea nitrogen/creatinine ratio increased? Renal function tests NOS abnormal? CSF was positive for Candida spp. Candidal meningitis? Candida test positive? MSSO-DI

92 Medication Errors See Appendix B of MedDRA Introductory Guide for Concept Descriptions Top-down navigation in HLGT Medication errors is best approach for term selection Medication error with clinical consequences Reported Patient was administered wrong drug and experienced hypotension Because of similar sounding drug names, the patient took the wrong drug and experienced a rash LLT Selected Wrong drug administered Hypotension Drug name confusion Wrong drug administered Rash MSSO-DI

93 Medication Errors (cont) Important to record occurrence or potential occurrence of medication error Medication error without clinical consequences Reported LLT Selected Comment Medication was given Intramuscular If specifically reported formulation that there is no adverse intravenously instead of administered by other effect, acceptable to intramuscularly without route select LLT No adverse sequelae No adverse effect effect Pharmacist notices that t the names of two drugs are similar and is concerned that this may result in a medication error Circumstance or information capable of leading to medication error LLT Drug name confusion could be an optional additional term to select. Note: this example is a potential medication error. MSSO-DI

94 Overdose, Toxicity and Poisoning If overdose,,poisoning or toxicity is explicitly reported, select the appropriate term Overdose with clinical consequences Reported Stomach upset from study drug overdose LLT Selected Stomach upset Overdose Overdose without clinical consequences Reported LLT Selected Comment Patient received an overdose of medicine without any adverse consequences Overdose No adverse effect LLT No adverse effect can also be selected MSSO-DI

95 What Term to Select? Doctor prescribed the wrong drug. The pharmacist noticed the error before giving the drug to the patient. Wrong drug administered? i d? Drug prescribing error? Intercepted drug prescribing error? Unintentionally took more than maximum recommended dose due to dispensing error Accidental overdose? Incorrect dose administered? Drug dispensing error? MSSO-DI

96 Medication Errors Reported to EudraVigilance (EV) Examined selected medication error terms from MedDRA (Overdose terms excluded) Grouped medication error terms related to medicines by Anatomical Therapeutic Chemical (ATC) classification system Retrieved individual cases reported to EV in postauthorisation phase (includes non-serious adverse reactions reported periodically for centrally authorised products (CAPs) in accordance with previous Volume 9A) MSSO-DI Acknowledgement: Dr. Sabine Brosch, EMA 96

97 Medication Error Cases in EudraVigilance Proportion of medication error reports ~ double from outside EEA MSSO-DI Acknowledgement: Dr. Sabine Brosch, EMA 97

98 Medication Errors by ATC Class * Examples: Medication errors associated with ATC Group Nervous System refer mainly to treatment non-compliance with antipsychotics ** Incorrect dosing *** Problems injecting immunosuppressant leading to incomplete dosing (No ADR) MSSO-DI Acknowledgement: Dr. Sabine Brosch, EMA 98

99 Medication Errors Associated with Serious ADRs % used as some products fall into more than one category MSSO-DI Acknowledgement: Dr. Sabine Brosch, EMA 99

100 Medication Errors by EMA Internal Groupings MSSO-DI Acknowledgement: Dr. Sabine Brosch, EMA 100

101 Misuse, Abuse and Addiction New MTS:PTC Section MSSO-DI

102 Coding Exercises Narratives and short verbatims Assess the reported terms Identify what concepts are reported (diagnosis, death, investigations, etc.) Refer to the appropriate sections of the MTS:PTC for guidance on term selection For example, Section 3.2 for death terms Use MTS:PTC preferred options (forget your organization s conventions) Use browser to search for and select LLTs (also record PT and primary SOC) MSSO-DI

103 Specific Tips for Narrative Exercises Overall, coding principles are the same as for short verbatim exercises Code all of the following: Events (including procedures and investigations as needed) Indications Medical history Social history MSSO-DI

104 Sample Narrative A 75-year-old male receiving Drug X for rheumatoid arthritis developed an area of darkened skin on his chest. The patient s medical history is significant for peripheral vascular disease and cigarette smoking. The skin lesion was excised; it was revealed to be a seborrhoeic wart. MSSO-DI

105 Course Summary In this course, we covered: A review of MedDRA s scope and structure, including primary SOC allocation rules Coding conventions, synonym lists, and coding QA Introduction to the MedDRA Term Selection: Points to Consider document Coding exercises MSSO-DI

106 Web site MSSO Contacts Telephone International AT&T Toll Free: Direct Dial (USA): Fax (USA) MSSO-DI

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

Coding with MedDRA 4/22/2015

Coding with MedDRA 4/22/2015 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities

More information

Introduction to MedDRA

Introduction to MedDRA Introduction to MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

Advanced MedDRA Coding

Advanced MedDRA Coding Advanced MedDRA Coding MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities

More information

Coding with MedDRA 3/2/2017

Coding with MedDRA 3/2/2017 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities

More information

Coding with MedDRA 3/6/2019

Coding with MedDRA 3/6/2019 Coding with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA

More information

MedDRA Overview A Standardized Terminology

MedDRA Overview A Standardized Terminology MedDRA Overview A Standardized Terminology Patrick Revelle Director, MedDRA MSSO 6 May 2010 MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations

More information

MedDRA Basic Concept

MedDRA Basic Concept MedDRA Basic Concept Pansie Zhang MSD R&D (China) Co., Ltd 23Apr2015 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not

More information

MedDRA Coding and Versioning

MedDRA Coding and Versioning MedDRA Coding and Versioning 4th ANNUAL INNOVATIONS IN CLINICAL DATA MANAGEMENT Alexandria, VA. 27-28 October 2016 Anna Zhao-Wong, MD, PhD Deputy Director of MedDRA MSSO anna.zhao-wong@meddra.org Agenda

More information

MedDRA - International standard for coding safety information. The Golden Triangle

MedDRA - International standard for coding safety information. The Golden Triangle MedDRA - International standard for coding safety information International Pharmacovigilance Conference Moscow, Russia 10 October 2018 Anna Zhao-Wong, MD, PhD MedDRA MSSO The Golden Triangle (MedDRA)

More information

Coding with MedDRA 1

Coding with MedDRA 1 Coding with Coding with MedDRA 1 4/3/2015 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals

More information

MedDRA Coding Quality: How to Avoid Common Pitfalls

MedDRA Coding Quality: How to Avoid Common Pitfalls MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

Coding with MedDRA 1

Coding with MedDRA 1 Coding with Coding with MedDRA 1 3/9/2017 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals

More information

Coding with MedDRA. Course Overview

Coding with MedDRA. Course Overview Coding with MedDRA MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Course Overview MedDRA background MedDRA s structure, scope,

More information

What s New MedDRA Version March

What s New MedDRA Version March C What s New MedDRA Version 21.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is registered by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and

More information

Data Analysis and Query Building with MedDRA

Data Analysis and Query Building with MedDRA Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The

More information

What Medical Writers Need to Know About MedDRA

What Medical Writers Need to Know About MedDRA What Medical Writers Need to Know About MedDRA Expert Seminar Series Session 2 40 th EMWA Conference, Dublin 6 May 2015 Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO MedDRA was developed under

More information

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Judy Harrison Chief Medical Officer MedDRA MSSO 22 October 2013 MedDRA Data

More information

What s New MedDRA Version March

What s New MedDRA Version March c What s New MedDRA Version 20.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

What s New MedDRA Version 13.1

What s New MedDRA Version 13.1 What s New MedDRA Version 13.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered

More information

Safety Data Analysis and Query Creation with MedDRA

Safety Data Analysis and Query Creation with MedDRA Safety Data Analysis and Query Creation with MedDRA Anne Kehely & Eva Rump Eli Lilly/MSSO 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Insert your logo in this area then delete this text

More information

Data Analysis and Query Building with MedDRA

Data Analysis and Query Building with MedDRA Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The

More information

What s New MedDRA Version MSSO-DI March 2016

What s New MedDRA Version MSSO-DI March 2016 c What s New MedDRA Version 19.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.13 Based on MedDRA Version 20.0 1 March 2017 Disclaimer and Copyright Notice This document is protected by copyright

More information

What s New MedDRA Version 18.0

What s New MedDRA Version 18.0 What s New MedDRA Version 18.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.4 Based on MedDRA Version 15.1 1 October 2012 Disclaimer and Copyright Notice This document is protected by copyright

More information

What s New MedDRA Version 15.1

What s New MedDRA Version 15.1 What s New MedDRA Version 15.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be

More information

Coding with Confidence

Coding with Confidence Coding with Confidence Hilary Vass (Global Clinical Dictionary Manager AstraZeneca UK Limited) Tomás Moraleda (Medical Officer MSSO) 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam Netherlands Disclaimer

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.8 Based on MedDRA Version 17.1 1 September 2014 Disclaimer and Copyright Notice This document is protected by copyright

More information

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.6 Based on MedDRA Version 16.1 1 October 2013 Disclaimer and Copyright Notice This

More information

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

MedDRA Term Selection: Latest activities of the Points to Consider Working Group MedDRA Term Selection: Latest activities of the Points to Consider Working Group Patrick Revelle MedDRA MSSO 23 May 2013 Overview The new EU pharmacovigilance legislation broadened the definition of an

More information

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr. Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI 23-24 EKİM 2003 Dr. Tomás Moraleda Agenda 1. What is MedDRA? 2. Conditions before MedDRA 3. MedDRA

More information

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.14 Based on MedDRA Version 20.1 1 September 2017 Disclaimer and Copyright Notice

More information

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.10 Based on MedDRA Version 11.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical and Social History

More information

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Judy Harrison, M.D. Chief Medical Officer MedDRA MSSO Information Day on Medication Errors 20 October 2016 London,

More information

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release draft Based on MedDRA version 7.1 ICH-Endorsed Guide for MedDRA Users on Data Output 18 November 2004 Copyright ICH Secretariat (c/o IFPMA)

More information

MedDRA: Safety Data Analysis and SMQs

MedDRA: Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

More information

MedDRA Safety Data Analysis and SMQs

MedDRA Safety Data Analysis and SMQs MedDRA Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration

More information

What s New MedDRA Version 14.0

What s New MedDRA Version 14.0 What s New MedDRA Version 14.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered

More information

Data retrieval using the new SMQ Medication Errors

Data retrieval using the new SMQ Medication Errors Data retrieval using the new SMQ Medication Errors Christina Winter Medical Director Safety Evaluation and Risk Management, GSK Information Day on Medication Errors 20 October 2016 London, UK Disclaimer

More information

Use of MedDRA in Special Situations

Use of MedDRA in Special Situations Use of MedDRA in Special Situations Patrick Revelle MedDRA MSSO 13 March 2012 Overview Existing terms in MedDRA for off-label use, abuse, misuse, overdose, and medication errors Current coding recommendations

More information

MedDRA: Safety Data Analysis and SMQs

MedDRA: Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

More information

Introductory Guide MedDRA Version 14.0

Introductory Guide MedDRA Version 14.0 Introductory Guide MedDRA Version 14.0 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory

More information

Frequently Asked Questions

Frequently Asked Questions Welcome to the European MedDRA Users Group Webinar on Update on Medication errors The session will be chaired by Ian Slack Liz Thomas from the MSSO will provide technical support Asking Questions Using

More information

Proposed MedDRA Version 17.0 Complex Changes (July 2013)

Proposed MedDRA Version 17.0 Complex Changes (July 2013) Proposed MedDRA Version 17.0 Complex Changes (July 2013) MedDRA User Submitted Requests: 1. Add a new HLT Exserohilum infections to HLGT Fungal infectious disorders Submitter rationale: Adding this HLT

More information

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016 Session 2 Data analysis based on overview of EudraVigilance data Victoria Newbould, EMA, EU Medication-errors workshop London, 20 October 2016 An agency of the European Union Acknowledgement Steven Le

More information

Introductory Guide MedDRA Version 15.0

Introductory Guide MedDRA Version 15.0 Introductory Guide MedDRA Version 15.0 Acknowledgements Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory

More information

Introductory Guide MedDRA Version 18.1

Introductory Guide MedDRA Version 18.1 Introductory Guide MedDRA Version 18.1 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory

More information

PHARMACOVIGILANCE GLOSSARY

PHARMACOVIGILANCE GLOSSARY PHARMACOVIGILANCE GLOSSARY Section 1 Section 2 Section 3 Section 4 Definitions of terminology used for side effects Definitions of drug safety terms Definitions of risk terminology Definitions of general

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release 1.4 Based on MedDRA Version 10.1 ICH-Endorsed Guide for MedDRA Users on Data Output 12 September 2007 Copyright ICH Secretariat (c/o IFPMA)

More information

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.8 Based on MedDRA Version 10.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical

More information

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 14.0 Terminology Frequency

More information

Perspective: E2B transmission

Perspective: E2B transmission Perspective: E2B transmission I2B(M) Information about the safety report itself A.1 Report identification A.2 Primary source of information A.3.1 Who sends the information A.3.2 Who receives it Case information

More information

Pharmacovigilance Methods and Post-Authorisation Safety Studies

Pharmacovigilance Methods and Post-Authorisation Safety Studies Pharmacovigilance Methods and Post-Authorisation Safety Studies Alex Dodoo Director, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance Accra, Ghana Objectives At the end of this module

More information

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes MedDRA 13.0 Review MedDRA Version Changes General Remarks MedDRA Version 13.0 Specific Changes Version 13.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 13.0 Terminology Frequency

More information

Search for studies: ClinicalTrials.gov Identifier: NCT

Search for studies: ClinicalTrials.gov Identifier: NCT ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Release 3.12 Based on MedDRA Version 12.0 ICH-Endorsed Guide for MedDRA Users Application to Adverse Drug Reactions /Adverse Events & Medical

More information

Medication Errors a challenge of pharmacovigilance BfArM experience

Medication Errors a challenge of pharmacovigilance BfArM experience Medication Errors a challenge of pharmacovigilance BfArM experience Dr. Claudia Kayser Federal Institute for Drugs and Medical Devices Medication safety / Pharmacovigilance 1 Disclosure Statement X I have

More information

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of

More information

Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU

Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data. Margaret Band, Clinical Trial Manager, TCTU Seeing Chickens at Window Recording Adverse Events and GeneratingQuality Data Margaret Band, Clinical Trial Manager, TCTU Adverse Event Reporting Monitoring of adverse events (AEs) is critical to the patient

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

This proposal represents a significant improvement over the previous version.

This proposal represents a significant improvement over the previous version. May 9, 2018 VIA ELECTRONIC MAIL Donna Pickett, MPH, RHIA ICD-10 Coordination and Maintenance Committee National Center for Health Statistics 3311 Toledo Road Hyattsville, Maryland 20782 Dear Ms. Pickett:

More information

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know MedDRA 10.1 Review MedDRA Version Changes General Remarks Terminology Files: What you need to know MedDRA Version 10.1 Specific Changes Version 10.1 Changes Overview Changes in a Nutshell Changes Highlights

More information

Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding

Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding Optum360 Learning: Detailed Instruction for Appropriate Coding An educational guide to the structure, conventions, and guidelines of coding 2017 Contents Section 1: Introduction...1 Documentation...7 Documentation

More information

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania. WHO-ART Magnus Wallberg November 24 th 2009 Dar Es Salaam, Tanzania magnus.wallberg@who-umc.org WHO-ART (WHO-Adverse Reaction Terminology) The need for a medical terminology dyspnoea? tinnitus ARDS fever

More information

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1 Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database

A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY

More information

Safety Assessment in Clinical Trials and Beyond

Safety Assessment in Clinical Trials and Beyond Safety Assessment in Clinical Trials and Beyond Yuliya Yasinskaya, MD Medical Team Leader Division of Anti-Infective Products Center for Drug Evaluation and Research FDA Clinical Investigator Training

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

ICD-10-CM Foundation Training

ICD-10-CM Foundation Training ICD-10-CM Foundation Training 1 Objectives What is ICD-10? Benefits of ICD-10 ICD-10 Impacts Important Facts about ICD-10 Where to Get More Information Codebook Structure Conventions Overview Code Structure

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A

More information

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD] SCREENING Visit Date: DEMOGRAPHICS / / [YYYY/MM/DD] Consent Signed Date and time / / [YYYY/MM/DD] : Has written assent been obtained? If no, why not? YES NO Gender: Male Female Birthdate: Permission given

More information

NEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting

NEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting The Pharmacovigilance Risk Assessment Committee (PRAC) Meeting 7-10 July 2014 Finalised safety procedure for methadone products containing povidone Only high molecular weight povidone was associated with

More information

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0) SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant

More information

Introduction to ICD-9 Code Selection. Laura Sullivan, CPC Coordinator Corporate Compliance Auditing & Education Summer 2010

Introduction to ICD-9 Code Selection. Laura Sullivan, CPC Coordinator Corporate Compliance Auditing & Education Summer 2010 Introduction to ICD-9 Code Selection Laura Sullivan, CPC Coordinator Corporate Compliance Auditing & Education Summer 2010 1 Legal Stuff The information provided here is personal opinion only and should

More information

Present-on-Admission (POA) Coding

Present-on-Admission (POA) Coding 1 Present-on-Admission (POA) Coding Michael Pine, MD, MBA Michael Pine and Associates, Inc 2 POA and Coding Guidelines (1) Unless otherwise specified, a POA modifier must be assigned to each principal

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Best practices in VeDDRA coding

Best practices in VeDDRA coding Best practices in VeDDRA coding 27 November 2013 Presented by: Giles Davis Chair of PhVWP-V VeDDRA sub-group An agency of the European Union Veterinary Dictionary for Drug Related Affairs SOC = System

More information

A chapter by chapter look at the ICD-10-CM code set Coding Tip Sheet

A chapter by chapter look at the ICD-10-CM code set Coding Tip Sheet Coding Tip Sheet Chapter 1 - Certain Infectious and Parasitic Diseases Terminology changes: The term Sepsis (ICD-10-CM) has replaced the term Septicemia (ICD-9-CM) Urosepsis is a nonspecific term and is

More information

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

Non-covered ICD-10-CM Codes for All Lab NCDs

Non-covered ICD-10-CM Codes for All Lab NCDs Non-covered ICD-10-CM s for All Lab NCDs This section lists codes that are never covered by Medicare for a diagnostic lab testing service. If a code from this section is given as the reason for the test,

More information

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy Assessment Prior to administration: Assess patient for chest pain, dysrhythmias, and vital signs (initially and throughout therapy) Obtain complete medical history, including allergies, especially heart

More information

Non-covered ICD-10-CM Codes for All Lab NCDs

Non-covered ICD-10-CM Codes for All Lab NCDs Non-covered ICD-10-CM s for All Lab NCDs This section lists codes that are never covered by Medicare for a diagnostic lab testing service. If a code from this section is given as the reason for the test,

More information

APR-DRG Description Ave Charge

APR-DRG Description Ave Charge Abdominal Pain 16,500.25 2.8 6,000.09 Acute & Subacute Endocarditis 15,339.30 3.0 5,113.10 Acute Myocardial Infarction 17,687.46 2.6 6,802.87 Alcohol Abuse & Dependence 19,126.64 4.2 4,553.96 Alcoholic

More information

Risk Management Plan Summary

Risk Management Plan Summary Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,

More information

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements

More information

Guideline on the Regulation of Therapeutic Products in New Zealand

Guideline on the Regulation of Therapeutic Products in New Zealand Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 January 2016 Section 1: Legislation Section summary This

More information

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010 January 2010 Version 2.0 Table of Contents 1. INTRODUCTION...1 1.1 Scope... 1 1.2 Purpose... 1 1.3 Responsibilities...

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)

PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin) ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8

More information

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding/ AE Log Item 1 Refresher ASPIRE Protocol Team Meeting February 10, 2013 MedDRA Coding Overview MedDRA: standardized dictionary of medical terminology Results from ICH initiative to standardize

More information

Routine signal detection and statistical tools on paediatrics

Routine signal detection and statistical tools on paediatrics Routine signal detection and statistical tools on paediatrics Paediatric workshop 28 April 2014 Presented by: Cosimo Zaccaria Signal Management Pharmacovigilance Department An agency of the European Union

More information

Adverse Event Terminology and Coding Working Group

Adverse Event Terminology and Coding Working Group Adverse Event Terminology and Coding Working Group March 2018 Working Group Chair: H. Ishikawa Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices Agency Overview of IMDRF

More information

Episodes of Care Risk Adjustment

Episodes of Care Risk Adjustment Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous

More information

Meet the Presenter. Welcome to PMI s Webinar Presentation. Understanding the ICD- 10-CM Guidelines. On the topic:

Meet the Presenter. Welcome to PMI s Webinar Presentation. Understanding the ICD- 10-CM Guidelines. On the topic: Welcome to PMI s Webinar Presentation Brought to you by: Practice Management Institute pmimd.com Meet the Presenter On the topic: Understanding the ICD- 10-CM Guidelines Libby Purser, CHI, CMC, CMIS, CMOM,

More information

ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy

ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Background Regulatory authorities

More information

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users Release 4.6 Based on MedDRA Version 16.1 1 October 2013 1 The following is a listing of changes made

More information